3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Prostatic Neoplasms
18
Brain Neoplasms
9
Glioblastoma
5
Glioma
4
Neoplasms
3
Uterine Cervical Neoplasms
2
Urogenital Diseases
2
Disease
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Prostate Adenocarcinoma
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Lobular
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Blood Specimen Collection
6
Prednisone
5
Positron Emission Tomography Computed Tomography
4
Mammography
4
Lenalidomide
4
Colonoscopy
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surveys and Questionnaires
3
Melphalan
3
Exercise
3
Biopsy
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Methods
2
Magnetic Resonance Imaging
2
Injections
2
Gemcitabine
2
Educational Status
2
Doxorubicin
2
Cytarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Disease
×
fluciclovine F-18
×
Clear all
NCT04410133
2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3
Completed
151 enrolled
29 charts
NCT04410367
2025-07-20
PURSUE
Blue Earth Diagnostics
Phase 2
Completed
23 enrolled
10 charts